Immune response to group A streptococcal C5a peptidase in children: implications for vaccine development.
Immune response to group A streptococcal C5a peptidase in children: implications for vaccine development.
复制标题
DOI：
10.1086/377700
复制
发表时间：
2003-09
期刊：
影响因子：
--
通讯作者：
A. Shet;E. L. Kaplan;Dwight R. Johnson;P. Cleary
中科院分区：
文献类型：
--
作者：
A. Shet;E. L. Kaplan;Dwight R. Johnson;P. Cleary
A 组链球菌 C5a 肽酶 (SCPA) 是一种主要的表面毒力蛋白，有助于 A 组链球菌 (GAS) 建立局部感染。我们使用标准化的间接酶联免疫吸附测定法测量了人体对 SCPA 的免疫反应。对来自患有 GAS 相关咽炎的儿童的配对急性和恢复期血清样本进行了分析，结果表明对 SCPA 的强烈免疫反应与感染的 M 型和患者年龄无关。细菌提取物的蛋白质印迹分析显示，所有测试的 M 型均表达 SCPA。对 SCPA 的免疫反应与抗链球菌溶血素 O 和抗 DNA 酶 B 反应相关。这些数据证实了 SCPA 对人类的免疫原性。先前对 SPCA 在毒力中的作用的了解、其高度保守的性质以及小鼠保护研究的结果使 SCPA 成为预防 GAS 疾病的理想候选疫苗。
The group A streptococcal C5a peptidase (SCPA) is a major surface virulence protein that facilitates the establishment of local infection by group A streptococci (GAS). We measured the human immune response to SCPA, using a standardized indirect enzyme-linked immunosorbent assay. Paired acute and convalescent serum samples from children with GAS-associated pharyngitis were assayed, and a strong immune response to SCPA was demonstrated that was independent of the infecting M type and the age of the patient. Western blot analysis of bacterial extracts revealed that all tested M types expressed SCPA. The immune response to SCPA correlated with the anti-streptolysin O and anti-DNase B responses. These data confirm the immunogenicity of SCPA in humans. Previous knowledge of SPCA's role in virulence, its highly conserved nature, and the results of mouse protection studies make SCPA an ideal vaccine candidate for the prevention of GAS disease.